Show simple item record

dc.contributor.authorTomlinson, OW
dc.contributor.authorWadey, CA
dc.contributor.authorWilliams, CA
dc.date.accessioned2022-12-05T12:06:17Z
dc.date.issued2022-12-02
dc.date.updated2022-12-03T14:58:02Z
dc.description.abstractObjective The importance of aerobic fitness (VO2peak) in cystic fibrosis (CF) is well established, and regular exercise testing is recommended. To standardise VO2peak, a ‘percentage of predicted’ (%pred) derived from normative reference values (NRV), as promoted by the 2015 European Cystic Fibrosis Society Exercise Working Group (ECFS EWG), can be reported. However, the NRVs used in CF and their relative frequency is unknown. Method A scoping review was performed via systematic database searches (PubMed, Embase, Web of Science, SciELO, EBSCO) and forward citation searches for studies that include people with CF and report VO2peak as %pred. Studies were screened using Covidence, and data related to patient demographics, testing modality and reference equations were extracted. Additional analyses were performed on studies published in 2016–2021, following the ECFS EWG statement in 2015. Results A total of 170 studies were identified, dating from 1984 to 2022, representing 6831 patients with CF, citing 34 NRV. Most studies (154/170) used cycle ergometry, 15/170 used treadmills, and the remainder used alternative, combination or undeclared modalities. In total, 61/170 failed to declare the NRV used. There were 61 studies published since the ECFS EWG statement, whereby 18/61 used the suggested NRV. Conclusion There is a wide discrepancy in NRV used in the CF literature base to describe VO2peak as %pred, with few studies using NRV from the ECFS EWG statement. This high variance compromises the interpretation and comparison of studies while leaving them susceptible to misinterpretation and limiting replication. Standardisation and alignment of reporting of VO2peak values are urgently needed.en_GB
dc.description.sponsorshipCanon Medical Systems UK Ltden_GB
dc.description.sponsorshipUniversity of Exeteren_GB
dc.format.extente001490-e001490
dc.identifier.citationVol. 8(4), article e001490en_GB
dc.identifier.doihttps://doi.org/10.1136/bmjsem-2022-001490
dc.identifier.urihttp://hdl.handle.net/10871/131946
dc.identifierORCID: 0000-0003-4063-7682 (Tomlinson, Owen W)
dc.language.isoenen_GB
dc.publisherBMJ Publishing Groupen_GB
dc.rights© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.en_GB
dc.titleNormal reference values for aerobic fitness in cystic fibrosis: a scoping reviewen_GB
dc.typeArticleen_GB
dc.date.available2022-12-05T12:06:17Z
dc.descriptionThis is the final version. Available on open access from BMJ publishing Group via the DOI in this recorden_GB
dc.descriptionData availability statement: All data relevant to the study are included in the article or uploaded as online supplemental information. Not applicable.en_GB
dc.identifier.eissn2055-7647
dc.identifier.journalBMJ Open Sport & Exercise Medicineen_GB
dc.relation.ispartofBMJ Open Sport & Exercise Medicine, 8(4)
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/en_GB
dcterms.dateAccepted2022-11-23
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2022-12-02
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2022-12-05T12:04:02Z
refterms.versionFCDVoR
refterms.dateFOA2022-12-05T12:06:18Z
refterms.panelAen_GB
refterms.dateFirstOnline2022-12-02


Files in this item

This item appears in the following Collection(s)

Show simple item record

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Except where otherwise noted, this item's licence is described as © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.